On our screens:Cheap stocks by free cash flow yield
The financials
Progyny, Inc. by the numbers
Progyny, Inc. (PGNY) reported revenue of $329M in Q1 2026 (quarter ended Mar 31, 2026), up 1.4% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $24M (7.4% of revenue). For the full year FY2025, revenue was $1.29B (+10% year on year) and net income $59M. Its largest product in Jun 2026 was Fertility Benefit Services at $230M, 66% of the disclosed total, well ahead of Pharmacy Benefit Services at 34%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $329M | $324M | +1.4% |
| Gross profit | $83M | $76M | +9.6% |
| Operating income | $35M | $24M | +46% |
| Net income | $24M | $15M | +61% |
| Diluted EPS | $0.29 | $0.17 | +71% |
| Product | Revenue | Share |
|---|---|---|
| Fertility Benefit Services | $230M | 66% |
| Pharmacy Benefit Services | $120M | 34% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $350.5M (+6.7%)
Fertility Benefit Services grew +7.6% year on yearPharmacy Benefit Services +1.2% year on year
Segment Latestquarter on quarteryear on year
- Fertility Benefit Services$230.2M$230.2MQoQ +9.9%year on year +7.6%+9.9%+7.6%
- Pharmacy Benefit Services$120.3M$120.3MQoQ +1.0%year on year +1.2%+1.0%+1.2%